Efficacy of Food Industry By-Product ß-Glucan/Chitin-Chitosan on Lipid Profile of Overweight and Obese Individuals: Sustainability and Nutraceuticals
Por:
Santisteban, V, Muñoz-Garcia, N, López-Yerena, A, Puntes, M, Badimon, L, Padro, T
Publicada:
1 oct 2024
Resumen:
Fat-binding nutraceutical supplements have gained considerable attention as potential cholesterol-lowering strategies to address dyslipidemia in overweight and obese individuals. This study aimed to evaluate the effects of a polysaccharide-rich compound containing beta-glucan/chitin-chitosan (beta GluCnCs) on lipid profiles and lipoprotein function. In a prospective, two-arm clinical trial, 58 overweight and obese individuals were randomized to receive either 3 g/day of beta GluCnCs or a placebo (microcrystalline cellulose) for 12 weeks. Serum lipids and lipoprotein functions were assessed at baseline and at 4-week intervals throughout the study. The administration of beta GluCnCs led to a significant increase in HDL cholesterol (HDLc) levels and improved HDLc/non-HDLc and HDLc/total cholesterol (TC) ratios, while reducing apolipoprotein B (ApoB) levels (p < 0.05). However, the intervention did not affect HDL particle diameter, particle number, or lipoprotein functionality. Women demonstrated greater sensitivity to changes in HDLc during beta GluCnCs supplementation, whereas men exhibited a significant reduction in ApoB levels. When stratified by baseline LDL cholesterol (LDLc) levels (cut-off: 130 mg/dL), the increase in HDLc and the ApoA1/ApoB ratio was found in the low-LDL group. In contrast, the high-LDL group experienced a significant reduction in atherogenic non-LDLc and LDLc, along with an improvement in HDL's antioxidant capacity after beta GluCnCs intervention. These changes were not statistically significant in the placebo group. In conclusion, our study demonstrated that daily supplementation with beta GluCnCs significantly improved lipid profiles, with effects that varied based on sex and baseline LDLc levels.
Filiaciones:
Santisteban, V:
Inst Recerca St Pau, Sant Antoni Ma Claret 167, Barcelona 08025, Spain
Univ Barcelona, Sch Pharm & Food Sci, Barcelona 08036, Spain
Muñoz-Garcia, N:
Inst Recerca St Pau, Sant Antoni Ma Claret 167, Barcelona 08025, Spain
López-Yerena, A:
Inst Recerca St Pau, Sant Antoni Ma Claret 167, Barcelona 08025, Spain
Puntes, M:
Inst Invest Biomed St Pau, Medicament Res Ctr CIM, Barcelona 08041, Spain
Badimon, L:
Inst Recerca St Pau, Sant Antoni Ma Claret 167, Barcelona 08025, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Cardiovasc, Madrid 28029, Spain
Univ Autonoma Barcelona, Cardiovasc Res Chair, Barcelona 08193, Spain
Padro, T:
Inst Recerca St Pau, Sant Antoni Ma Claret 167, Barcelona 08025, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Cardiovasc, Madrid 28029, Spain
gold
|